[24] György M Keserő and Gergely M Makara. Hit discovery and hit-to-lead approaches. *Drug discovery today*, 11(15-16):741-748, 2006.
[25] Asher Mullard. How much do phase iii trials cost? Nature Reviews. Drug Discovery, 17(11): 777-777, 2018.
[26] Linda Martin, Melissa Hutchens, Conrad Hawkins, and Alaina Radnov. How much do clinical trials cost. Nat Rev Drug Discov, 16(6):381-382, 2017.
[27] Jiankun Lyu, Sheng Wang, Trent E Balius, Isha Singh, Anat Levit, Yurii S Moroz, Matthew J O'Meara, Tao Che, Enkhjargal Algaa, Kateryna Tolmachova, et al. Ultra-large library docking for discovering new chemotypes. Nature, 566(7743):224-229, 2019.
[28] Felix Wong, Satotaka Omori, Nina M Donghia, Erica J Zheng, and James J Collins. Discovering small-molecule senolytics with deep neural networks. Nature Aging, pages 1-17, 2023.
[29] Gary Liu, Denise B Catacutan, Khushi Rathod, Kyle Swanson, Wengong Jin, Jody C Mohammed, Anush Chiappino-Pepe, Saad A Syed, Meghan Fragis, Kenneth Rachwalski, et al. Deep learning-guided discovery of an antibiotic targeting acinetobacter baumannii. Nature Chemical Biology, pages 1-9, 2023.
[30] RD Brown and YC Martin. An evaluation of structural descriptors and clustering methods for use in diversity selection. SAR and QSAR in Environmental Research, 8(1-2):23-39, 1998.
[31] Bie Verbist, Günter Klambauer, Liesbet Vervoort, Willem Talloen, Ziv Shkedy, Olivier Thas, Andreas Bender, Hinrich WH Gohlmann, Sepp Hochreiter, QSTAR Consortium, et al. Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the qstar project. Drug discovery today, 20(5):505-513, 2015.
[32] George Papadatos, Anthony WJ Cooper, Visakan Kadirkamanathan, Simon JF Macdonald, Iain M McLay, Stephen D Pickett, John M Pritchard, Peter Willett, and Valerie J Gillet. Analysis of neighborhood behavior in lead optimization and array design. Journal of chemical information and modeling, 49(2):195-208, 2009.
[33] Nathan Brown, Marco Fiscato, Marwin HS Segler, and Alain C Vaucher. Guacamol: benchmarking models for de novo molecular design. Journal of chemical information and modeling, 59(3):1096-1108, 2019.
[34] Tianfan Fu, Cao Xiao, Xinhao Li, Lucas M Glass, and Jimeng Sun. Mimosa: Multi-constraint molecule sampling for molecule optimization. In Proceedings of the AAAI Conference on Artificial Intelligence, volume 35, pages 125-133, 2021.
[35] Wengong Jin, Regina Barzilay, and Tommi Jaakkola. Junction tree variational autoencoder for molecular graph generation. In International conference on machine learning, pages 2323-2332. PMLR, 2018.
[36] Maxime Langevin, Hervé Minoux, Maximilien Levesque, and Marc Biancotto. Scaffolding-constrained molecular generation. Journal of Chemical Information and Modeling, 60(12): 5637-5646, 2020.
[37] William J Godinez, Eric J Ma, Alexander T Chao, Luying Pei, Peter Skewes-Cox, Stephen M Canham, Jeremy L Jenkins, Joseph M Young, Eric J Martin, and W Armand Guiguemde. Design of potent antimalarials with generative chemistry. Nature Machine Intelligence, 4(2):180-186, 2022.
[38] Wenhao Gao, Tianfan Fu, Jimeng Sun, and Connor Coley. Sample efficiency matters: a benchmark for practical molecular optimization. Advances in Neural Information Processing Systems, 35:21342-21357, 2022.
[39] David E Patterson, Richard D Cramer, Allan M Ferguson, Robert D Clark, and Laurence E Weinberger. Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. Journal of medicinal chemistry, 39(16):3049-3059, 1996.